CA2871659C — Inhibitor of jak1 and jak2
Assigned to Eli Lilly and Co · Expires 2017-04-04 · 9y expired
What this patent protects
The present invention provides an amino pyrazole compound, which is 3-[(lR)-6-fluoro-2,3-dihydro-1H-inden-l-yl]-N-(3- methyl-IH- pyrazol-5-yl)-3H-imidazo[4,5-b]pyridin-5-amine, or a pharmaceutically acceptable salt thereof, that inhibits JAK1 and JAK2 and, therefore may be useful…
USPTO Abstract
The present invention provides an amino pyrazole compound, which is 3-[(lR)-6-fluoro-2,3-dihydro-1H-inden-l-yl]-N-(3- methyl-IH- pyrazol-5-yl)-3H-imidazo[4,5-b]pyridin-5-amine, or a pharmaceutically acceptable salt thereof, that inhibits JAK1 and JAK2 and, therefore may be useful in treating cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.